Patient Square Capital LP Invests $4 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Patient Square Capital LP purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 121,732 shares of the biopharmaceutical company's stock, valued at approximately $4,000,000. Agios Pharmaceuticals makes up about 1.5% of Patient Square Capital LP's portfolio, making the stock its 11th biggest holding. Patient Square Capital LP owned approximately 0.21% of Agios Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AGIO. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth about $33,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals in the fourth quarter worth about $53,000. Sterling Capital Management LLC increased its holdings in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 1,587 shares during the last quarter. KBC Group NV increased its holdings in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 611 shares during the last quarter. Finally, AlphaQuest LLC raised its stake in Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after buying an additional 2,338 shares in the last quarter.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

AGIO has been the subject of several research reports. Scotiabank decreased their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $56.00.

Agios Pharmaceuticals Trading Down 1.4%

AGIO opened at $28.74 on Wednesday. The business's 50 day moving average is $29.03 and its 200-day moving average is $37.00. The stock has a market cap of $1.66 billion, a PE ratio of 2.53 and a beta of 0.77. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The firm had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.